MX2018002068A - Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. - Google Patents
Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.Info
- Publication number
- MX2018002068A MX2018002068A MX2018002068A MX2018002068A MX2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A
- Authority
- MX
- Mexico
- Prior art keywords
- fkpa
- polypeptides
- methods
- purification
- multispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
Abstract
La presente invención proporciona métodos para producir polipéptidos de peptidil-prolil cis/trans isomerasa del tipo FKBP (FkpA) con niveles de pureza muy elevados. También se proporciona FkpA ultrapura y métodos para utilizarla, por ejemplo, para uso en inmunoanálisis para mostrar la eliminación de FkpA de productos biológicos producidos en bacterias. Además, la presente invención proporciona métodos para purificar polipéptidos (por ejemplo, anticuerpos multiespecíficos) producidos en bacterias que sobreexpresan una o más chaperonas. Los métodos incluyen cromatografía de afinidad, cromatografía de modo mixto y cromatografía de interacción hidrófoba. En algunos aspectos, la invención proporciona composiciones de polipéptidos (por ejemplo, anticuerpos multiespecíficos) que están esencialmente libres de impurezas específicas del producto.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562207910P | 2015-08-20 | 2015-08-20 | |
US201562207908P | 2015-08-20 | 2015-08-20 | |
US201562210378P | 2015-08-26 | 2015-08-26 | |
PCT/US2016/047912 WO2017031476A2 (en) | 2015-08-20 | 2016-08-19 | Purification of fkpa and uses thereof for producing recombinant polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018002068A true MX2018002068A (es) | 2018-06-06 |
Family
ID=58052052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018002068A MX2018002068A (es) | 2015-08-20 | 2016-08-19 | Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180327446A1 (es) |
EP (1) | EP3337819B1 (es) |
JP (2) | JP7091238B2 (es) |
KR (1) | KR20180048731A (es) |
CN (1) | CN108473558A (es) |
AU (1) | AU2016308383A1 (es) |
BR (1) | BR112018003127A2 (es) |
CA (1) | CA2995385A1 (es) |
HK (1) | HK1259368A1 (es) |
IL (2) | IL257400A (es) |
MX (1) | MX2018002068A (es) |
TW (1) | TW201718623A (es) |
WO (1) | WO2017031476A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
EP3092049A1 (en) | 2014-01-08 | 2016-11-16 | Flodesign Sonics Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
ES2905105T3 (es) * | 2017-12-29 | 2022-04-07 | Hoffmann La Roche | Procedimiento para proporcionar una composición de proteína PEGilada |
WO2019166932A1 (en) * | 2018-02-27 | 2019-09-06 | Pfizer Inc. | Antibody purification |
AU2019240135A1 (en) * | 2018-03-21 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Separation of VWF and VWF propeptide by chromatographic methods |
WO2019193418A1 (en) | 2018-04-05 | 2019-10-10 | Bio-Rad Abd Serotec Gmbh | Display systems for proteins of interest |
WO2020064865A1 (en) * | 2018-09-25 | 2020-04-02 | Ichnos Sciences S.A. | Antibody quantification in biological samples |
CN114409798A (zh) * | 2019-02-14 | 2022-04-29 | 美勒斯公司 | 制备包含两种或更多种抗体的组合物 |
JP2022525775A (ja) | 2019-03-18 | 2022-05-19 | バイオ-ラッド エービーディー セロテック ゲーエムベーハー | SpyTag含有ペリプラズム融合タンパク質のプロテアーゼTSP及びOMPT分解からの保護 |
KR20220002581A (ko) * | 2019-05-03 | 2022-01-06 | 제넨테크, 인크. | 정제 플랫폼으로부터 수득된 조성물의 효소적 가수분해 활성 속도를 감소시키는 방법 |
JP2023510133A (ja) * | 2019-12-20 | 2023-03-13 | メルク・シャープ・アンド・ドーム・エルエルシー | エンテロウイルスの精製組成物、およびグルタチオンアフィニティークロマトグラフィーによる精製方法 |
EP4118093A4 (en) * | 2020-03-11 | 2024-04-17 | Dr Reddys Laboratories Ltd | METHOD FOR PURIFYING A FC FUSION PROTEIN |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2312494T3 (es) * | 2000-12-14 | 2009-03-01 | Genentech, Inc. | Produccion de anticuerpos completos en celulas procariotas. |
WO2009136286A2 (en) * | 2008-05-05 | 2009-11-12 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
CA2911256A1 (en) * | 2008-10-20 | 2010-12-09 | Robert K. Hickman | Isolation and purification of antibodies using protein a affinity chromatography |
MX2012004711A (es) * | 2009-10-20 | 2012-05-23 | Abbott Lab | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a. |
WO2013028330A2 (en) * | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
BR112014011900A2 (pt) * | 2011-12-15 | 2017-05-16 | Hanwha Chemical Corp | um método de purificação de anticorpo |
UY34558A (es) * | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
BR112015015948B1 (pt) * | 2013-01-09 | 2022-05-17 | Takeda Pharmaceutical Company Limited | Método de purificação da proteína arilsulfatase a (asa) recombinante |
RU2015141529A (ru) * | 2013-04-05 | 2017-05-15 | Дженентек, Инк. | Антитела и биспецифические антитела к il-4 и их применение |
AU2014253785B2 (en) * | 2013-04-19 | 2018-07-19 | Sutro Biopharma, Inc. | Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones |
CN105473612A (zh) * | 2013-08-19 | 2016-04-06 | 豪夫迈·罗氏有限公司 | 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物 |
WO2015038888A1 (en) * | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
WO2015070068A1 (en) * | 2013-11-07 | 2015-05-14 | Abbvie Inc. | Isolation and purification of antibodies |
KR20160124165A (ko) * | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
-
2016
- 2016-08-19 KR KR1020187007920A patent/KR20180048731A/ko not_active Application Discontinuation
- 2016-08-19 AU AU2016308383A patent/AU2016308383A1/en not_active Abandoned
- 2016-08-19 BR BR112018003127A patent/BR112018003127A2/pt not_active IP Right Cessation
- 2016-08-19 TW TW105126681A patent/TW201718623A/zh unknown
- 2016-08-19 JP JP2018509536A patent/JP7091238B2/ja active Active
- 2016-08-19 CA CA2995385A patent/CA2995385A1/en not_active Abandoned
- 2016-08-19 MX MX2018002068A patent/MX2018002068A/es unknown
- 2016-08-19 WO PCT/US2016/047912 patent/WO2017031476A2/en active Application Filing
- 2016-08-19 CN CN201680061356.3A patent/CN108473558A/zh active Pending
- 2016-08-19 EP EP16758343.4A patent/EP3337819B1/en active Active
-
2018
- 2018-02-07 IL IL257400A patent/IL257400A/en unknown
- 2018-02-16 US US15/932,222 patent/US20180327446A1/en not_active Abandoned
-
2019
- 2019-01-31 HK HK19101736.6A patent/HK1259368A1/zh unknown
-
2021
- 2021-11-17 IL IL288205A patent/IL288205A/en unknown
-
2022
- 2022-01-13 JP JP2022003518A patent/JP2022062046A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201718623A (zh) | 2017-06-01 |
IL257400A (en) | 2018-04-30 |
WO2017031476A3 (en) | 2017-04-13 |
KR20180048731A (ko) | 2018-05-10 |
IL288205A (en) | 2022-01-01 |
HK1259368A1 (zh) | 2019-11-29 |
AU2016308383A1 (en) | 2018-03-15 |
US20180327446A1 (en) | 2018-11-15 |
EP3337819C0 (en) | 2024-02-21 |
JP2022062046A (ja) | 2022-04-19 |
WO2017031476A2 (en) | 2017-02-23 |
EP3337819B1 (en) | 2024-02-21 |
EP3337819A2 (en) | 2018-06-27 |
CN108473558A (zh) | 2018-08-31 |
JP7091238B2 (ja) | 2022-06-27 |
JP2018533355A (ja) | 2018-11-15 |
BR112018003127A2 (pt) | 2018-09-25 |
CA2995385A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018002068A (es) | Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. | |
AU2017286676A8 (en) | Purification of multispecific antibodies | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
WO2016033225A3 (en) | Antibodies, compositions, and uses | |
WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
PH12016502482A1 (en) | Process for the purification of tnfr:fc fusion protein | |
MX2017011189A (es) | Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos. | |
EA201500943A1 (ru) | Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов | |
MX2018011162A (es) | Metodos de purificacion de colageno 7. | |
MX2020010724A (es) | Metodos para preparar composiciones proteicas estables. | |
WO2018162557A3 (en) | Method for purifying proteins using silicate | |
EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
MX2020005653A (es) | Compuestos para la separacion de elementos de tierras raras y metales s, p, d, metodo de separacion y uso de estos. | |
WO2016161415A3 (en) | Tnfrsf14/ hvem proteins and methods of use thereof | |
EA201990998A1 (ru) | Фармацевтические составы и способы их получения | |
WO2016033437A3 (en) | Polyethers, polyamines, polythioethers, and methods for making same | |
MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
MX2022012042A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
WO2017079443A8 (en) | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same | |
MY183011A (en) | Novel purification process of gonadotropin | |
EA201792366A1 (ru) | Способ разделения белка и прочих примесей и капсульных полисахаридов микроорганизмов | |
EA201890177A1 (ru) | Мультиспецифические связывающие белки | |
MX2017013511A (es) | Proceso para reducir la concentracion de 1233xf en 244bb. | |
SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
NZ631116A (en) | Process for preparing apolipoprotein a-i (apo a-i) |